Hypomorphic MGAT5 polymorphisms promote multiple sclerosis cooperatively with MGAT1 and interleukin-2 and 7 receptor variants

Journal of Neuroimmunology

Volumn 256, Issue 1-2, 2013, Pages 71-76

  Li, Carey F ^a   Zhou, Raymond W ^a   Mkhikian, Haik ^a   Newton, Barbara L ^a   Yu, Zhaoxia ^b   Demetriou, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

Interleukin 2 receptor; Interleukin 7 receptor; MGAT1; MGAT5; Multiple sclerosis; N glycosylation

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ENZYME; GLYCAN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA; MGAT1 ENZYME; MGAT5 ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; ENVIRONMENTAL FACTOR; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GOLGI COMPLEX; HEREDITY; HUMAN; HUMAN CELL; INTRON; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; VITAMIN D DEFICIENCY;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; CTLA-4 ANTIGEN; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GALACTOSYLTRANSFERASES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; N-ACETYLGLUCOSAMINYLTRANSFERASES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-7; RISK FACTORS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84875370134     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.12.008     Document Type: Article

References (36)

1. Anjos S., Nguyen A., Ounissi-Benkalha H., Tessier M.C., Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem. 2002, 277:46478-46486.
2. Baranzini S.E., Mudge J., van Velkinburgh J.C., Khankhanian P., Khrebtukova I., Miller N.A., Zhang L., Farmer A.D., Bell C.J., Kim R.W., May G.D., Woodward J.E., Caillier S.J., McElroy J.P., Gomez R., Pando M.J., Clendenen L.E., Ganusova E.E., Schilkey F.D., Ramaraj T., Khan O.A., Huntley J.J., Luo S., Kwok P.Y., Wu T.D., Schroth G.P., Oksenberg J.R., Hauser S.L., Kingsmore S.F. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010, 464:1351-1356.
3. Brynedal B., Wojcik J., Esposito F., Debailleul V., Yaouanq J., Martinelli-Boneschi F., Edan G., Comi G., Hillert J., Abderrahim H. MGAT5 alters the severity of multiple sclerosis. J. Neuroimmunol. 2010, 220:120-124.
4. Chen I.J., Chen H.L., Demetriou M. Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J. Biol. Chem. 2007, 282:35361-35372.
5. Chen H.L., Li C.F., Grigorian A., Tian W., Demetriou M. T cell receptor signaling co-regulates multiple Golgi genes to enhance N-glycan branching. J. Biol. Chem. 2009, 284:32454-32461.
6. Cummings R.D., Kornfeld S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J. Biol. Chem. 1982, 257:11230-11234.
7. Demetriou M., Granovsky M., Quaggin S., Dennis J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001, 409:733-739.
8. Dennis J.W., Nabi I.R., Demetriou M. Metabolism, cell surface organization, and disease. Cell 2009, 139:1229-1241.
9. Ebers G.C., Bulman D.E., Sadovnick A.D., Paty D.W., Warren S., Hader W., Murray T.J., Seland T.P., Duquette P., Grey T., et al. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 1986, 315:1638-1642.
10. Esposito F., Wojcik J., Rodegher M., Radaelli M., Moiola L., Ghezzi A., Capra R., Brambilla P., Sorosina M., Giacalone G., Martinelli V., Comi G., Abderrahim H., Martinelli Boneschi F. MGAT5 and disease severity in progressive multiple sclerosis. J. Neuroimmunol. 2011, 230:143-147.
11. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., Haines J.L. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 2007, 39:1083-1091.
12. Grigorian A., Demetriou M. Mgat5 deficiency in T cells and experimental autoimmune encephalomyelitis. ISRN Neurol. 2011, 374314.
13. Grigorian A., Lee S.U., Tian W., Chen I.J., Gao G., Mendelsohn R., Dennis J.W., Demetriou M. Control of T Cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J. Biol. Chem. 2007, 282:20027-20035.
14. Grigorian A., Torossian S., Demetriou M. T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol. Rev. 2009, 230:232-246.
15. Grigorian A., Araujo L., Naidu N.N., Place D., Choudhury B., Demetriou M. N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) responses and treats experimental autoimmune encephalomyelitis. J. Biol. Chem. 2011, 286:40133-40141.
16. Grigorian A., Mkhikian H., Demetriou M. Interleukin-2, Interleukin-7, T cell-mediated autoimmunity, and N-glycosylation. Ann. N. Y. Acad. Sci. 2012, 1253:49-57.
17. Grigorian A., Mkhikian H., Li C.F., Newton B.L., Zhou R.W., Demetriou M. Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation. Semin. Immunopathol. 2012, 34:415-424.
18. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
19. International Multiple Sclerosis Genetics Consortium Genome-wide association study of severity in multiple sclerosis. Genes Immun. 2011, 12:615-625.
20. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
21. Lau K.S., Partridge E.A., Grigorian A., Silvescu C.I., Reinhold V.N., Demetriou M., Dennis J.W. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 2007, 129:123-134.
22. Lee S.U., Grigorian A., Pawling J., Chen I.J., Gao G., Mozaffar T., McKerlie C., Demetriou M. N-glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration. J. Biol. Chem. 2007, 282:33725-33734.
23. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39:1108-1113.
24. Madsen L.S., Andersson E.C., Jansson L., Krogsgaard M., Andersen C.B., Engberg J., Strominger J.L., Svejgaard A., Hjorth J.P., Holmdahl R., Wucherpfennig K.W., Fugger L. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 1999, 23:343-347.
25. Maier L.M., Anderson D.E., Severson C.A., Baecher-Allan C., Healy B., Liu D.V., Wittrup K.D., De Jager P.L., Hafler D.A. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol. 2009, 182:1541-1547.
26. Maier L.M., Lowe C.E., Cooper J., Downes K., Anderson D.E., Severson C., Clark P.M., Healy B., Walker N., Aubin C., Oksenberg J.R., Hauser S.L., Compston A., Sawcer S., De Jager P.L., Wicker L.S., Todd J.A., Hafler D.A. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 2009, 5:e1000322.
27. Maurer M., Loserth S., Kolb-Maurer A., Ponath A., Wiese S., Kruse N., Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002, 54:1-8.
28. Mkhikian H., Grigorian A., Li C.F., Chen H.L., Newton B., Zhou R.W., Beeton C., Torossian S., Tatarian G.G., Lee S.U., Lau K., Walker E., Siminovitch K.A., Chandy K.G., Yu Z., Dennis J.W., Demetriou M. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat. Commun. 2011, 2:334.
29. Morgan R., Gao G., Pawling J., Dennis J.W., Demetriou M., Li B. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J. Immunol. 2004, 173:7200-7208.
30. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
31. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 2007, 165:1097-1109.
32. Smolders J., Damoiseaux J., Menheere P., Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 2008, 194:7-17.
33. Soilu-Hanninen M., Airas L., Mononen I., Heikkila A., Viljanen M., Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 2005, 11:266-271.
34. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2001, 2:762-764.
35. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Simmons R., Taylor B.V., Butzkueven H., Kilpatrick T. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003, 327:316.
36. Yu, Z., Gillen, D., Li, C.F., Demetriou, M., in press. Incorporating parental information into family-based association tests. Biostatistics. http://dx.doi.org/10.1093/biostatistics/kxs048.